TY - JOUR T1 - Personalised prediction of daily eczema severity scores using a mechanistic machine learning model JF - medRxiv DO - 10.1101/2020.01.16.20017772 SP - 2020.01.16.20017772 AU - Guillem Hurault AU - Elisa Domínguez-Hüttinger AU - Sinéad M. Langan AU - Hywel C. Williams AU - Reiko J. Tanaka Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/01/18/2020.01.16.20017772.abstract N2 - Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with periods of flares and remission. Designing personalised treatment strategies for AD is challenging, given the apparent unpredictability and large variation in AD symptoms and treatment responses within and across individuals. Better prediction of AD severity over time for individual patients could help to select optimum timing and type of treatment for improving disease control.Objective We aimed to develop a mechanistic machine learning model that predicts the patient-specific evolution of AD severity scores on a daily basis.Methods We designed a probabilistic predictive model and trained it using Bayesian inference with the longitudinal data from two published clinical studies. The data consisted of daily recordings of AD severity scores and treatments used by 59 and 334 AD children over 6 months and 16 weeks, respectively. Internal and external validation of the predictive model was conducted in a forward-chaining setting.Results Our model was able to predict future severity scores at the individual level and improved chance-level forecast by 60%. Heterogeneous patterns in severity trajectories were captured with patient-specific parameters such as the short-term persistence of AD severity and responsiveness to topical steroids, calcineurin inhibitors and step-up treatment.Conclusion Our proof of principle model successfully predicted the daily evolution of AD severity scores at an individual level, and could inform the design of personalised treatment strategies that can be tested in future studies.Competing Interest StatementRJT receives funding from Pierre Fabre and Leo Foundation. SML is supported by a Wellcome Senior Research Fellowship in Clinical Science (205039/Z/16/Z). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funders. SML was also supported by Health Data Research UK (grant No. LOND1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust.Funding StatementThis work was supported by British Skin Foundation (grant number 005/R/18).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the codes will be made available on GitHub. ER -